

# Familial Mediterranean Fever - Pipeline Insight, 2021

https://marketpublishers.com/r/FEA31CC2BBB7EN.html

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: FEA31CC2BBB7EN

## **Abstracts**

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Familial Mediterranean Fever - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Familial Mediterranean Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

## **Geography Covered**

Global coverage

Familial Mediterranean Fever Understanding

Familial Mediterranean Fever: Overview

Familial Mediterranean fever (FMF) is an inherited auto inflammatory disease characterized by recurrent episodes (attacks) of fever and acute inflammation of the membranes lining the abdomen, joints, and lungs. Some individuals may develop a serious condition known as amyloidosis, in which certain proteins called amyloid accumulates in various tissues of the body. It is caused by mutations of the MEFV gene. There is no cure for FMF, but there are effective treatments. Specific treatments are aimed at the specific symptoms apparent in each individual. Non-steroidal anti-inflammatory drugs (NSAIDs) and pain medications (analgesics) can be used to treat individuals during a febrile or inflammatory episode.



"Familial Mediterranean Fever- Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Familial Mediterranean Fever pipeline landscape is provided which includes the disease overview and Familial Mediterranean Fever treatment guidelines. The assessment part of the report embraces, in depth Familial Mediterranean Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Familial Mediterranean Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## **Report Highlights**

The companies and academics are working to assess challenges and seek opportunities that could influence Familial Mediterranean Fever R&D. The therapies under development are focused on novel approaches to treat/improve Familial Mediterranean Fever.

Familial Mediterranean Fever Emerging Drugs Chapters

This segment of the Familial Mediterranean Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Familial Mediterranean Fever Emerging Drugs

Tocilizumab: Roche

aciliar mach is a recombinant burganizad managland antibady II. Crease

Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.

Further product details are provided in the report......

Familial Mediterranean Fever: Therapeutic Assessment

This segment of the report provides insights about the different Familial Mediterranean



Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Familial Mediterranean Fever

There are approx. 3+ key companies which are developing the therapies for Familial Mediterranean Fever. The companies which have their Familial Mediterranean Fever drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Roche and others.

#### **Phases**

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

#### **Route of Administration**

Familial Mediterranean Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as


Subcutaneous

Intravenous

Oral

Parenteral





### **Pipeline Development Activities**

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Familial Mediterranean Fever drugs.

Familial Mediterranean Fever Report Insights

Familial Mediterranean Fever Pipeline Analysis



Therapeutic Assessment
Unmet Needs
Impact of Drugs

Familial Mediterranean Fever Report Assessment

**Pipeline Product Profiles** 

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

**Unmet Needs** 

## **Key Questions**

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Familial Mediterranean Fever drugs?

How many Familial Mediterranean Fever drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Familial Mediterranean Fever?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Familial Mediterranean Fever therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?



What are the clinical studies going on for Familial Mediterranean Fever and their status?

What are the key designations that have been granted to the emerging drugs?

# **Key Players**

Roche

# **Key Products**

Tocilizumab



## **Contents**

Introduction

**Executive Summary** 

Familial Mediterranean Fever: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Familial Mediterranean Fever – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Familial Mediterranean Fever companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Familial Mediterranean Fever Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

**Product Description** 

Research and Development

**Product Development Activities** 

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Tocilizumab: Roche

**Product Description** 

Research and Development

**Product Development Activities** 

Drug profiles in the detailed report.....



Pre-clinical and Discovery Stage Products

Comparative Analysis

**Product Description** 

Research and Development

**Product Development Activities** 

Drug profiles in the detailed report.....

**Inactive Products** 

Comparative Analysis

Familial Mediterranean Fever Key Companies

Familial Mediterranean Fever Key Products

Familial Mediterranean Fever- Unmet Needs

Familial Mediterranean Fever- Market Drivers and Barriers

Familial Mediterranean Fever- Future Perspectives and Conclusion

Familial Mediterranean Fever Analyst Views

Familial Mediterranean Fever Key Companies

Appendix



# **List Of Tables**

#### LIST OF TABLES

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

**Table 12 Inactive Products** 



# **List Of Figures**

#### LIST OF FIGURES

Figure '	1 Total	Products	for	Familial	Mediterra	nean Fever
----------	---------	----------	-----	----------	-----------	------------

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products



### I would like to order

Product name: Familial Mediterranean Fever - Pipeline Insight, 2021

Product link: https://marketpublishers.com/r/FEA31CC2BBB7EN.html

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/FEA31CC2BBB7EN.html">https://marketpublishers.com/r/FEA31CC2BBB7EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970